Title: Critical illness-related bone loss is associated with osteoclastic and angiogenic abnormalities
Authors: Owen, Helen ×
Vanhees, Ine
Solie, L
Roberts, S J
Wauters, A
Luyten, Frank
Van Cromphaut, Sophie
Van den Berghe, Greet #
Issue Date: Jul-2012
Publisher: Blackwell Science, Inc.
Series Title: Journal of Bone and Mineral Research vol:27 issue:7 pages:1541-1552
Article number: 10.1002/jbmr.1612
Abstract: Critically ill patients are at increased risk of fractures during rehabilitation, and can experience impaired healing of traumatic and surgical bone fractures. In addition, markers of bone resorption are markedly increased in critically ill patients, whilst markers of bone formation are decreased. In the current study, we have directly investigated the effect of critical illness on bone metabolism and repair. In a human in vitro model of critical illness, FACS analysis revealed an increase in circulating CD14 + /CD11b+ osteoclast precursors in critically ill patient peripheral blood compared to healthy controls. In addition, the formation osteoclasts was increased in patient peripheral blood mononuclear cell (PBMC) cultures compared to healthy controls, both in the presence and absence of osteoclastogenic factors RANKL and M-CSF. Culturing PBMCs with 10% critically ill patient serum further increased osteoclast formation and activity in patient PBMCs only, and neutralization studies revealed that IgG antibody signaling through the immunoreceptor Fc receptor common γ chain III (FcRγIII) played an important role. When analyzing bone formation, no differences in osteogenic differentiation were observed using human periosteal-derived cells (hPDCs) treated with patient serum in vitro, but a decrease in the expression of VEGF-R1 suggested impaired vascularization. This was confirmed using serum-treated hPDCs implanted onto calcium phosphate scaffolds in a murine in vivo model of bone formation, where decreased vascularization and increased osteoclast activity led to a decrease in bone formation in scaffolds with patient serum-treated hPDCs. Together, these findings may help to define novel therapeutic targets to prevent bone loss and optimize fracture healing in critically ill patients. © 2012 American Society for Bone and Mineral Research.
ISSN: 0884-0431
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Cell and Gene Therapy Applications (-)
Laboratory of Intensive Care Medicine
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
OA_JBMR_Jul_2012_Owen.pdfOA article Published 1792KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science